BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31271118)

  • 1. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer.
    Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L
    Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.
    Kim N; Kim JS; Geol Lee C
    PLoS One; 2020; 15(7):e0236350. PubMed ID: 32687531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
    Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer.
    Kozak MM; Murphy JD; Schipper ML; Donington JS; Zhou L; Whyte RI; Shrager JB; Hoang CD; Bazan J; Maxim PG; Graves EE; Diehn M; Hara WY; Quon A; Le QT; Wakelee HA; Loo BW
    J Thorac Oncol; 2011 May; 6(5):920-6. PubMed ID: 21774104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
    Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
    Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Nygård L; Vogelius IR; Fischer BM; Kjær A; Langer SW; Aznar MC; Persson GF; Bentzen SM
    J Thorac Oncol; 2018 Apr; 13(4):559-567. PubMed ID: 29355615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.
    Ito H; Matsuo Y; Ohtsu S; Nishimura T; Terada Y; Sakamoto T; Mizowaki T
    Int J Clin Oncol; 2020 Feb; 25(2):274-281. PubMed ID: 31667664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of
    Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
    Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
    Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
    Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy.
    Grewal AS; Min EJ; Long Q; Grewal SK; Jain V; Levin WP; Cengel KA; Swisher-McClure S; Aggarwal C; Bauml JM; Singh A; Ciunci C; Cohen RB; Langer C; Feigenberg SJ; Berman AT
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):358-368. PubMed ID: 31654783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
    Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
    Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial.
    Jouglar E; Isnardi V; Goulon D; Ségura-Ferlay C; Ayadi M; Dupuy C; Douillard JY; Mahé MA; Claude L
    Radiother Oncol; 2018 Feb; 126(2):291-299. PubMed ID: 29203290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.